Back to Avelumab

Avelumab

Showing 3 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Chiang et al.	2023	Prospective	Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial	10.1016/s2468-1253(22)00339-9	—	33	68	HCC	primary	Anti-PD-(L)1 mAb	Avelumab	also TACE	33	extra-cranial	liver	—	30	30	35	5	5	5	—	—	—	Treatment-rel.	—	—	11	G3: 24 AE, G4: 9 AE	G3: 3 pt, G4: 8 pt	any G3: ascites, weight gained, dizziness, hoarseness, maculopapular rash, urticarial rash, pruritis, dry skin, nausea, alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma-glutamyl transferase increased, bilirubin increased, Alkaline phosphatase increased, hepatitis, dermatitis, any G4: weight gained, dizziness, hoarseness, Alanine aminotransferase increased, Aspartate aminotransferase increased, Hyponatraemia	—
Rimner et al.	2023	Prospective	A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma	10.1016/j.jtocrr.2022.100440	NCT03399552	13	71	other	any	Anti-PD-(L)1 mAb	Avelumab	—	13	both	Missing	—	30	24	35	3	3	5	10.0	Missing	Missing	Treatment-rel.	—	—	2	any G3: 4 AEs	any G3: 2 pts	any G3: Infusion-related allergic reaction, chest wall pain, myalgia, anorexia	any G3: Chest wall pain
Kwan et al.	2022	Prospective	Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial	10.1016/j.eururo.2021.08.011	ACTRN12618000954224	31	71	Prostate cancer	oligometastatic	Anti-PD-(L)1 mAb	Avelumab	—	31	extra-cranial	bone	—	20	20	20	1	1	1	20.0	20	20	Treatment-rel.	—	—	5	Missing	any G3 or G4: 5 pt	any G3 or G4: Infusion related reaction, bone pain, maculopapular rash, hyperglycemia, pneumonitis	—